AdminSep 2, 2020< 1 min read

Aetion adds another $19M to its Series B to make sense of drug development and treatment data

AlleyWatch caught up with CEO Carolyn Magill to learn more about how the company powers regulators, biopharma, payers, and health technology assessment (HTA) bodies, the company’s future plans, and Aetion’s Series B, which brings the total round size to $82B extension.

Read More

Aetion adds another $19M to its Series B to make sense of drug development and treatment data

Admin

RELATED ARTICLES